# Rockefeller University: Phase 1 study in Fanconi Anemia, Head and Neck Cancer (80 participants)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Rockefeller University |
| Sponsor type | Academic and hospital |
| Study | Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia |
| NCT ID | NCT07901959 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Fanconi Anemia; Head and Neck Cancer; Squamous Cell Carcinoma; Squamous Cell Cancer of Head and Neck (SCCHN) |
| Intervention types | drug |
| Target enrollment | 80 |
| Site countries | United States |
| Posted | 2026-10-28 |
| Planned start | 2026-10-14 |
| Event | Newly registered study |
| Event date | 2026-10-28 |

## Why this score
- Posted in the last two weeks.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07901959). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.